((自动化翻译由路透提供，请见免责声明 ))
10月11日 - ** 摩根大通将制药公司Ultragenyx Pharmaceutical 的PT值从94美元上调至105美元，与该股上次收盘价相比上涨了约95%。
** 摩根大通自5月份以来首次上调RARE的PT - LSEG
** 券商认为 公司的药物 setrusumab 很有可能在治疗成骨不全症研究的三个触发点中的至少一个点上显示出统计学意义。
** 成骨不全症是一种遗传性疾病，会导致骨骼容易断裂
** 根据医生的反馈，只要在任何一个触发点上达到统计学意义 根据医生的反馈，只要在任何一个触发点上达到统计意义上的显著性，就足以推动有意义的采用 - JPM
** JPM 预计峰值收入约为 12 亿美元，并假定该药物的成功概率约为 80%。
** 跟踪 RARE 的 21 位分析师的平均评级为 "买入"；PT 中位数为 79 美元 - LSEG
** 截至上一交易日收盘，股价累计上涨约 13
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.